drugset / Trial / NCT05872256
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
NaSingle-groupOpen-labelTreatment
Summary
The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2023-11-13
- Completion
- 2023-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Halobetasol | Unknown | 0.01 % | Topical |
| Subject | Tazarotene | Small molecule | 0.045 % | Topical |